Trials / No Longer Available
No Longer AvailableNCT03363334
Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP
Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Rigel Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
C-935788-055 is an open-label, multi-center, expanded access (EAP) study.
Detailed description
The purpose of the program is to provide Fostamatinib in an Expanded Access setting to subjects who meet the selection criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fostamatinib disodium 100 mg | Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) |
| DRUG | Fostamatinib disodium 150 mg | Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) |
Timeline
- First posted
- 2017-12-06
- Last updated
- 2018-08-01
Source: ClinicalTrials.gov record NCT03363334. Inclusion in this directory is not an endorsement.